Zobrazeno 1 - 10
of 3 034
pro vyhledávání: '"Shionoya A"'
Autor:
Kaho Shionoya, Jae-Hyun Park, Toru Ekimoto, Junko S. Takeuchi, Junki Mifune, Takeshi Morita, Naito Ishimoto, Haruka Umezawa, Kenichiro Yamamoto, Chisa Kobayashi, Atsuto Kusunoki, Norimichi Nomura, So Iwata, Masamichi Muramatsu, Jeremy R. H. Tame, Mitsunori Ikeguchi, Sam-Yong Park, Koichi Watashi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Macaque restricts hepatitis B virus (HBV) infection because its receptor homologue, NTCP (mNTCP), cannot bind preS1 on viral surface. To reveal how mNTCP loses the viral receptor function, we here solve the cryo-electron microscopy structure
Externí odkaz:
https://doaj.org/article/e0c7a1cde5a344788f48548a8d8535bf
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
ObjectiveTo identify any correlations between evidence levels, adoption rates, and additional costs of in vitro fertilization (IVF) add-ons.DesignOnline survey.SubjectsThe survey was conducted in 621 assisted reproductive technology-registered facili
Externí odkaz:
https://doaj.org/article/228c6933fe6148fb9d1b90900e6f125a
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Chemical etching of nano-sized metal clusters at the atomic level has a high potential for creating metal number-specific structures and functions that are difficult to achieve with bottom-up synthesis methods. In particular, precisely etchi
Externí odkaz:
https://doaj.org/article/8160e09562b24e9e8f8da06d28d0953b
Autor:
Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 15, Iss 12, Pp 987-993 (2024)
Abstract Background Pemetrexed (PEM) is the primary chemotherapy for non‐small cell lung cancer (NSCLC), showing potential for long‐term disease stability in certain cases. However, studies examining disease control with PEM therapy are lacking.
Externí odkaz:
https://doaj.org/article/6fc1ea41a0b142279a109622e0964639
Autor:
Yu Shionoya, Megumi Katsumata, Hajime Kasai, Kohei Shikano, Aoi Hino, Masaki Suzuki, Mitsuhiro Abe, Takuji Suzuki
Publikováno v:
Radiology Case Reports, Vol 19, Iss 2, Pp 567-571 (2024)
Radiation-induced organizing pneumonia is a rare complication of radiation therapy for thoracic cancer. Carbon-ion radiotherapy, an emerging treatment modality for early-stage lung cancer treatment, can also cause lung injuries. However, as cases of
Externí odkaz:
https://doaj.org/article/75b2df47dfdb4925be73a45120c2980d
Publikováno v:
In Brain Behavior and Immunity August 2024 120:464-470
Autor:
Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 36, Pp 3549-3555 (2023)
Abstract Background Several options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are
Externí odkaz:
https://doaj.org/article/3dfcc8af26d449629347ab88334f53e4
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Molecular twist is a characteristic component of molecular machines. Selectively synthesising isomers with different modes of twisting and controlling their motion such as helicity inversion is an essential challenge for achieving more advan
Externí odkaz:
https://doaj.org/article/fc8a112c88134ca7b5f06eb6ed446cfb
Publikováno v:
ACS Organic & Inorganic Au, Vol 3, Iss 6, Pp 371-376 (2023)
Externí odkaz:
https://doaj.org/article/800aeab92b7f4bdf95504c753a2f0503
Autor:
Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2754-2760 (2023)
Abstract Background Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of
Externí odkaz:
https://doaj.org/article/a909f4025c2145fc8914aa045dfc6961